Trisequens

How to order Trisequens

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Trisequens on Prescriptsy

Trisequens is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Trisequens is a sequential combined hormone replacement therapy (HRT) tablet containing estradiol and norethisterone acetate.

It is licensed in the United Kingdom for the relief of oestrogen-deficiency symptoms associated with the menopause and for the prevention of postmenopausal osteoporosis in women at increased risk of fractures.

Trisequens provides continuous oestrogen replacement with cyclical progestogen to protect the endometrium, producing a predictable monthly withdrawal bleed.

It is suitable for perimenopausal women who are still menstruating (even irregularly) and for postmenopausal women with an intact uterus.

The menopause affects all women, typically occurring between the ages of 45 and 55, with the average age in the UK being 51.

Approximately 75% of women experience vasomotor symptoms (hot flushes and night sweats), and many also experience urogenital atrophy, mood disturbance, sleep disruption, and joint aches.

An estimated 1.5 million women in the UK currently use HRT to manage these symptoms.

This page provides a comprehensive clinical overview of Trisequens, covering how it works, dosing guidance, expected bleeding patterns, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Trisequens

Before reading further, note the following key safety points about Trisequens.

• Trisequens is for women with an intact uterus only. Women who have had a hysterectomy should use oestrogen-only HRT.
• Do not skip or omit the white (progestogen-containing) tablets, as the progestogen is essential for endometrial protection.
• HRT is associated with small increased risks of venous thromboembolism, breast cancer (with combined HRT beyond 5 years), and stroke. These risks must be weighed against the benefits for each individual.
• Seek emergency medical help (call 999) if you develop sudden chest pain, breathlessness, leg swelling, sudden severe headache, visual disturbance, or weakness on one side of the body.

Understanding the menopause

The menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity.

It is confirmed retrospectively after 12 consecutive months of amenorrhoea in the absence of other pathological or physiological causes.

The perimenopause (or menopausal transition) is the period leading up to the final menstrual period, during which hormonal fluctuations cause increasingly irregular cycles and the onset of menopausal symptoms.

Postmenopause begins after the final menstrual period and continues for the remainder of life.

The decline in ovarian oestrogen production is the central event driving menopausal symptoms.

Oestrogen receptors are distributed throughout the body, including the brain (thermoregulatory centre), urogenital tract, cardiovascular system, skeleton, skin, and joints.

Oestrogen deficiency therefore produces a wide range of symptoms: vasomotor instability (hot flushes and night sweats), urogenital atrophy (vaginal dryness, dyspareunia, urinary frequency and urgency), mood changes (irritability, anxiety, low mood), sleep disturbance, cognitive changes, musculoskeletal pain, and accelerated bone loss leading to osteoporosis.

Menopause management in the UK

NICE Guideline NG23 (Menopause: diagnosis and management) provides the framework for menopause care in the UK.

It recommends that HRT should be offered as the first-line treatment for vasomotor symptoms and that the risks and benefits should be discussed on an individual basis.

NICE emphasises that the benefits of HRT generally outweigh the risks for most women under 60 years of age or within 10 years of their last period.

The guideline also notes that HRT should be offered for the prevention of osteoporosis in women with premature ovarian insufficiency (menopause before 40) or early menopause (before 45).

How Trisequens works

Oestrogen replacement: estradiol

Estradiol, the oestrogen component of Trisequens, is chemically identical to the 17-beta-estradiol produced by the human ovary.

After oral absorption, estradiol undergoes first-pass metabolism in the liver, where a proportion is converted to oestrone and oestrone sulphate, which act as circulating reservoirs for subsequent conversion back to estradiol.

Estradiol binds to nuclear oestrogen receptors (ER-alpha and ER-beta), forming a receptor complex that modulates the transcription of target genes involved in thermoregulation, tissue maintenance, bone metabolism, and cardiovascular function.

The clinical effects of estradiol replacement include resolution or significant reduction of hot flushes and night sweats, reversal of urogenital atrophy, improvement in mood and sleep quality, preservation of bone mineral density, and improvement in skin hydration and connective tissue integrity.

Trisequens contains estradiol 2 mg in the blue and white tablets and estradiol 1 mg in the red tablets, providing continuous oestrogen cover throughout each 28-day cycle.

Endometrial protection: norethisterone acetate

In women with an intact uterus, unopposed oestrogen stimulation of the endometrium increases the risk of endometrial hyperplasia and, with prolonged use, endometrial carcinoma.

Adding a progestogen for a minimum of 10 to 14 days per cycle opposes this proliferative effect, inducing secretory transformation and orderly shedding of the endometrium (a withdrawal bleed).

This protective effect is the primary reason for the progestogen component of Trisequens.

Norethisterone acetate is a synthetic progestogen derived from 19-nortestosterone.

It is converted to norethisterone in the body, which binds to progesterone receptors and exerts progestogenic effects on the endometrium.

The 10-day course of norethisterone acetate 1 mg in each Trisequens cycle (the white tablets) is sufficient to provide effective endometrial protection when used in conjunction with the estradiol component.

Clinical evidence and national guidelines

Sequential combined HRT has been used in clinical practice for over four decades and is supported by extensive evidence from randomised controlled trials and observational studies.

The Women's Health Initiative (WHI), the Heart and Estrogen/progestin Replacement Study (HERS), and the Million Women Study have informed current understanding of the benefits and risks of HRT.

While these studies raised awareness of certain risks (particularly VTE and breast cancer with long-term use), subsequent reanalysis and newer data from the WHI age-stratified analyses have established that the risk-benefit profile is most favourable for women who start HRT within 10 years of menopause onset or before age 60.

NICE NG23 recommends HRT as the first-line treatment for vasomotor symptoms, noting that the benefits of symptom relief generally outweigh the risks for women under 60.

The guideline also states that HRT can be offered for osteoporosis prevention in women at risk who cannot take other treatments, and that all women should receive individualised counselling about the benefits and risks.

The British Menopause Society (BMS) endorses these recommendations and provides further guidance on HRT prescribing, monitoring, and duration of use.

Who is Trisequens suitable for

Trisequens is designed for women with an intact uterus who require oestrogen replacement for menopausal symptoms or osteoporosis prevention.

The sequential regimen, which produces a monthly withdrawal bleed, is particularly appropriate for perimenopausal women (those who are still menstruating, even if irregularly) and for women in early postmenopause.

Women who are well established in postmenopause (typically more than 12 months since last natural period) may prefer continuous combined HRT (such as Kliovance), which aims to avoid regular bleeding.

The choice between sequential and continuous combined HRT should be discussed with the prescriber.

Trisequens is not suitable for women who have had a hysterectomy (who should use oestrogen-only HRT), women with contraindications to HRT (see Warnings section), or women seeking contraception (HRT does not provide reliable contraception).

Dosage and administration

The Trisequens pack contains 28 tablets arranged in a calendar strip.

Take one tablet daily, starting with the 12 blue tablets, followed by the 10 white tablets, and finishing with the 6 red tablets.

Start the next pack immediately with no gap. Tablets should be swallowed whole with water at approximately the same time each day.

Taking the tablet at bedtime may help reduce awareness of any nausea, which is more common during the initial weeks of treatment.

A withdrawal bleed is expected during or shortly after the red-tablet phase of each cycle.

The timing, duration, and heaviness of this bleed may vary between cycles, particularly during the first few months.

If bleeding occurs at unexpected times, persists beyond 6 months, or becomes unusually heavy, consult your prescriber for further assessment.

Side effects of Trisequens

Common side effects

Side effects are most common during the first three to six months of treatment as the body adjusts to the hormonal regimen.

Common effects include breast tenderness and enlargement, headache, nausea, abdominal bloating, leg cramps, mood changes, and breakthrough bleeding or spotting outside the expected withdrawal bleed.

These effects usually diminish with continued use. If they persist or cause significant distress, consult your prescriber, who may adjust the preparation or route of administration.

Less common side effects

Weight changes, fluid retention, changes in libido, dizziness, migraine, skin changes (including chloasma, acne, or pruritus), vaginal candidiasis, and hair changes (thinning or increased growth) have been reported. Contact lens wearers may notice changes in corneal curvature affecting lens tolerance.

Serious adverse effects

Venous thromboembolism: Combined oral HRT is associated with approximately a two to threefold increase in VTE risk compared with non-use.

The absolute risk is approximately 1 to 2 additional cases per 1,000 women per year. Risk is highest during the first year and in women with predisposing factors.

Symptoms of DVT include unilateral leg swelling, pain, and warmth; symptoms of PE include sudden breathlessness, pleuritic chest pain, and haemoptysis. Call 999 immediately if these occur.

Breast cancer: Combined HRT used for more than 5 years is associated with a small increase in breast cancer risk, estimated at approximately 8 additional cases per 10,000 women-years.

The risk decreases after stopping and returns to baseline within approximately 5 years. Regular self-examination and attendance at NHS Breast Screening are important.

Stroke: Oral HRT is associated with a small increase in ischaemic stroke risk, estimated at approximately 1 to 3 additional cases per 1,000 women over 5 years.

This risk is more relevant for women over 60 or those starting HRT more than 10 years after menopause.

Recognise stroke symptoms using the FAST test: Face drooping, Arm weakness, Speech difficulty, Time to call 999.

Endometrial cancer: The progestogen component of Trisequens protects against oestrogen-induced endometrial hyperplasia and carcinoma. Omitting or skipping the progestogen phase increases this risk. Report any unscheduled or unexplained vaginal bleeding to your prescriber promptly.

Warnings and precautions

Contraindications

Trisequens must not be used in women with known or suspected breast cancer, other oestrogen-dependent neoplasia, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active or previous VTE (unless on anticoagulant therapy with careful specialist oversight), active arterial thromboembolic disease (stroke, myocardial infarction, angina), acute liver disease, known thrombophilic disorders, or porphyria.

Conditions requiring careful monitoring

If you have any of the following, HRT may be appropriate but requires closer monitoring: fibroids (may enlarge), endometriosis (may be reactivated), history of cholestatic jaundice or gallstones, migraine or severe headache (especially migraine with aura), hypertension, diabetes mellitus, epilepsy, asthma, otosclerosis, systemic lupus erythematosus, or a strong family history of breast cancer.

Your prescriber will assess whether the benefits of HRT outweigh the risks in your individual case.

Contraception

Trisequens does not provide contraception.

Perimenopausal women may still ovulate occasionally and should use appropriate non-hormonal contraception (such as condoms or a copper intrauterine device) until contraception is no longer required.

NICE and the Faculty of Sexual and Reproductive Healthcare recommend continuing contraception for 2 years after the last natural period in women under 50, and for 1 year in women over 50.

Surgery and immobilisation

If you are scheduled for elective surgery requiring prolonged immobilisation (such as major orthopaedic or abdominal surgery), discuss stopping Trisequens 4 to 6 weeks before the procedure with your prescriber.

Do not resume until you are fully mobile. VTE prophylaxis measures should be discussed with your surgical team.

How to obtain Trisequens in the UK

Trisequens is a prescription-only medicine (POM).

You can obtain a prescription from your GP, an NHS or private menopause clinic, or an authorised online prescriber registered with the GPhC and CQC.

A clinical assessment covering your menopausal symptoms, medical history, cardiovascular risk factors, family history (especially breast cancer and VTE), and current medications is required before prescribing.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living well through the menopause

HRT is a highly effective treatment for menopausal symptoms, but it works best as part of a broader approach to health and wellbeing during the menopausal transition.

Regular weight-bearing and resistance exercise helps maintain bone density, cardiovascular fitness, and mood.

A balanced diet rich in calcium (at least 700 mg per day) and vitamin D supports bone health. Maintaining a healthy weight reduces vasomotor symptoms and cardiovascular risk.

Limiting alcohol and caffeine may reduce the frequency and severity of hot flushes.

Cognitive behavioural therapy (CBT) has been shown in NICE-cited evidence to reduce the impact of hot flushes and night sweats, and may be offered alongside or as an alternative to HRT for some women.

If you experience low mood, anxiety, or sleep disturbance during the menopause, discuss this with your GP.

These symptoms often improve with HRT, but additional psychological support or treatment may be beneficial.

Many NHS trusts now operate dedicated menopause clinics with specialist nurses and doctors, and voluntary organisations such as the British Menopause Society and the Daisy Network (for premature ovarian insufficiency) provide reliable information and support.

When to seek urgent medical advice

Call 999 or attend A&E immediately if you develop sudden chest pain or breathlessness (possible pulmonary embolism), sudden severe headache, visual disturbance, or weakness on one side of the body (possible stroke), or painful swelling in one leg (possible deep vein thrombosis).

Contact your GP or NHS 111 if you experience unusual vaginal bleeding, a new breast lump, persistent headaches, or symptoms of jaundice (yellowing of the skin or eyes, dark urine, pale stools).

Report any suspected adverse reactions to Trisequens via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Trisequens, Summary of Product Characteristics (EMC)
• Estradiol with Norethisterone, British National Formulary (BNF)
• NICE NG23: Menopause: diagnosis and management
• Menopause, NHS
• British Menopause Society
• MHRA Yellow Card Scheme